When does GenSight report and what matters for SIGHT.PA stock?

GenSight reports earnings on **21 Jan 2026**. Investors will focus on R&D spending, cash runway, and clinical updates for LUMEVOQ and GS030. Any guidance or partner deals will most affect SIGHT.PA stock.

What is Meyka AI's forecast for SIGHT.PA stock?

Meyka AI's forecast model projects **€0.13** monthly. Versus the current price **€0.0915**, that implies an upside of **42.08%**. Forecasts are model-based and not guarantees.

What are realistic price targets for SIGHT.PA stock?

Near-term targets: Bear **€0.05**, Base **€0.10**, Bull **€0.25**. Targets reflect trial risk, funding status, and potential partnership news ahead of earnings.

What main risks could hurt SIGHT.PA stock after earnings?

Main risks are adverse clinical news, heavier-than-expected cash burn, and lack of funding or partnership updates. Low liquidity can amplify negative moves in SIGHT.PA stock.

EU Stocks

SIGHT.PA GenSight Biologics EURONEXT 19 Jan 2026: pre-market ahead of earnings

ByHuzaifa Zahoor January 19, 2026January 19, 2026

SIGHT.PA stock trades at €0.0915 pre-market on 19 Jan 2026 as investors position for GenSight Biologics’ earnings due 21 Jan 2026. Market action is light with volume near 1,244,840 shares and a one-day move of +3.62%. The upcoming report is the main catalyst in EURONEXT trading and will test clinical progress, cash burn, and guidance for 2026.